Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1985 Nov;28(5):716–721. doi: 10.1128/aac.28.5.716

The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.

D C Hooper, J S Wolfson
PMCID: PMC176369  PMID: 2936302

Full text

PDF
716

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adhami Z. N., Wise R., Weston D., Crump B. The pharmacokinetics and tissue penetration of norfloxacin. J Antimicrob Chemother. 1984 Jan;13(1):87–92. doi: 10.1093/jac/13.1.87. [DOI] [PubMed] [Google Scholar]
  2. Aronoff G. E., Kenner C. H., Sloan R. S., Pottratz S. T. Multiple-dose ciprofloxacin kinetics in normal subjects. Clin Pharmacol Ther. 1984 Sep;36(3):384–388. doi: 10.1038/clpt.1984.192. [DOI] [PubMed] [Google Scholar]
  3. Bailey R. R., Kirk J. A., Peddie B. A. Norfloxacin-induced rheumatic disease. N Z Med J. 1983 Jul 27;96(736):590–590. [PubMed] [Google Scholar]
  4. Barre J., Houin G., Tillement J. P. Dose-dependent pharmacokinetic study of pefloxacin, a new antibacterial agent, in humans. J Pharm Sci. 1984 Oct;73(10):1379–1382. doi: 10.1002/jps.2600731014. [DOI] [PubMed] [Google Scholar]
  5. Boerema J. B., Dalhoff A., Debruyne F. M. Ciprofloxacin distribution in prostatic tissue and fluid following oral administration. Chemotherapy. 1985;31(1):13–18. doi: 10.1159/000238308. [DOI] [PubMed] [Google Scholar]
  6. Bologna M., Vaggi L., Forchetti C. M., Martini E. Bactericidal intraprostatic concentrations of norfloxacin. Lancet. 1983 Jul 30;2(8344):280–280. doi: 10.1016/s0140-6736(83)90258-1. [DOI] [PubMed] [Google Scholar]
  7. Brumfitt W., Franklin I., Grady D., Hamilton-Miller J. M., Iliffe A. Changes in the pharmacokinetics of ciprofloxacin and fecal flora during administration of a 7-day course to human volunteers. Antimicrob Agents Chemother. 1984 Nov;26(5):757–761. doi: 10.1128/aac.26.5.757. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Crider S. R., Colby S. D., Miller L. K., Harrison W. O., Kerbs S. B., Berg S. W. Treatment of penicillin-resistant Neisseria gonorrhoeae with oral norfloxacin. N Engl J Med. 1984 Jul 19;311(3):137–140. doi: 10.1056/NEJM198407193110301. [DOI] [PubMed] [Google Scholar]
  9. Crump B., Wise R., Dent J. Pharmacokinetics and tissue penetration of ciprofloxacin. Antimicrob Agents Chemother. 1983 Nov;24(5):784–786. doi: 10.1128/aac.24.5.784. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Davies B. I., Maesen F. P., Teengs J. P. Serum and sputum concentrations of enoxacin after single oral dosing in a clinical and bacteriological study. J Antimicrob Chemother. 1984 Sep;14 (Suppl 100):83–89. doi: 10.1093/jac/14.suppl_c.83. [DOI] [PubMed] [Google Scholar]
  11. Deaney N. B., Vogel R., Vandenburg M. J., Currie W. J. Norfloxacin in acute urinary tract infections. Practitioner. 1984 Jan;228(1387):111–117. [PubMed] [Google Scholar]
  12. Eandi M., Viano I., Di Nola F., Leone L., Genazzani E. Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage. Eur J Clin Microbiol. 1983 Jun;2(3):253–259. doi: 10.1007/BF02029528. [DOI] [PubMed] [Google Scholar]
  13. Fillastre J. P., Hannedouche T., Leroy A., Humbert G. Pharmacokinetics of norfloxacin in renal failure. J Antimicrob Chemother. 1984 Oct;14(4):439–439. doi: 10.1093/jac/14.4.439. [DOI] [PubMed] [Google Scholar]
  14. Giamarellou H., Tsagarakis J., Petrikkos G., Daikos G. K. Norfloxacin versus cotrimoxazole in the treatment of lower urinary tract infections. Eur J Clin Microbiol. 1983 Jun;2(3):266–269. doi: 10.1007/BF02029530. [DOI] [PubMed] [Google Scholar]
  15. Gilfillan E. C., Pelak B. A., Bland J. A., Malatesta P. F., Gadebusch H. H. Pharmacokinetic studies of norfloxacin in laboratory animals. Chemotherapy. 1984;30(5):288–296. doi: 10.1159/000238283. [DOI] [PubMed] [Google Scholar]
  16. Goldstein E. J., Alpert M. L., Ginsberg B. P. Norfloxacin versus trimethoprim-sulfamethoxazole in the therapy of uncomplicated, community-acquired urinary tract infections. Antimicrob Agents Chemother. 1985 Mar;27(3):422–423. doi: 10.1128/aac.27.3.422. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Gonzalez M. A., Uribe F., Moisen S. D., Fuster A. P., Selen A., Welling P. G., Painter B. Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers. Antimicrob Agents Chemother. 1984 Nov;26(5):741–744. doi: 10.1128/aac.26.5.741. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Guerra J. G., Falconi E., Palomino J. C., Benavente L., Antunez de Mayolo E. Clinical evaluation of norfloxacin versus cotrimoxazole in urinary tract infections. Eur J Clin Microbiol. 1983 Jun;2(3):260–265. doi: 10.1007/BF02029529. [DOI] [PubMed] [Google Scholar]
  19. Haase D. A., Harding G. K., Thomson M. J., Kennedy J. K., Urias B. A., Ronald A. R. Comparative trial of norfloxacin and trimethoprim-sulfamethoxazole in the treatment of women with localized, acute, symptomatic urinary tract infections and antimicrobial effect on periurethral and fecal microflora. Antimicrob Agents Chemother. 1984 Oct;26(4):481–484. doi: 10.1128/aac.26.4.481. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Handsfield H. H., Judson F. N., Holmes K. K. Treatment of uncomplicated gonorrhea with rosoxacin. Antimicrob Agents Chemother. 1981 Nov;20(5):625–629. doi: 10.1128/aac.20.5.625. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Hoogkamp-Korstanje J. A., van Oort H. J., Schipper J. J., van der Wal T. Intraprostatic concentration of ciprofloxacin and its activity against urinary pathogens. J Antimicrob Chemother. 1984 Dec;14(6):641–645. doi: 10.1093/jac/14.6.641. [DOI] [PubMed] [Google Scholar]
  22. Höffken G., Lode H., Prinzing C., Borner K., Koeppe P. Pharmacokinetics of ciprofloxacin after oral and parenteral administration. Antimicrob Agents Chemother. 1985 Mar;27(3):375–379. doi: 10.1128/aac.27.3.375. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Höffler D., Dalhoff A., Gau W., Beermann D., Michl A. Dose- and sex-independent disposition of ciprofloxacin. Eur J Clin Microbiol. 1984 Aug;3(4):363–366. doi: 10.1007/BF01977496. [DOI] [PubMed] [Google Scholar]
  24. Joos B., Ledergerber B., Flepp M., Bettex J. D., Lüthy R., Siegenthaler W. Comparison of high-pressure liquid chromatography and bioassay for determination of ciprofloxacin in serum and urine. Antimicrob Agents Chemother. 1985 Mar;27(3):353–356. doi: 10.1128/aac.27.3.353. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Kirby C. P. Treatment of simple urinary tract infections in general practice with a 3-day course of norfloxacin. J Antimicrob Chemother. 1984 May;13 (Suppl B):107–112. doi: 10.1093/jac/13.suppl_b.107. [DOI] [PubMed] [Google Scholar]
  26. Ledergerber B., Bettex J. D., Joos B., Flepp M., Lüthy R. Effect of standard breakfast on drug absorption and multiple-dose pharmacokinetics of ciprofloxacin. Antimicrob Agents Chemother. 1985 Mar;27(3):350–352. doi: 10.1128/aac.27.3.350. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Leigh D. A., Emmanuel F. X. The treatment of Pseudomonas aeruginosa urinary tract infections with norfloxacin. J Antimicrob Chemother. 1984 May;13 (Suppl B):85–88. doi: 10.1093/jac/13.suppl_b.85. [DOI] [PubMed] [Google Scholar]
  28. Leigh D. A., Smith E. C., Marriner J. Comparative study using norfloxacin and amoxycillin in the treatment of complicated urinary tract infections in geriatric patients. J Antimicrob Chemother. 1984 May;13 (Suppl B):79–83. doi: 10.1093/jac/13.suppl_b.79. [DOI] [PubMed] [Google Scholar]
  29. Lockley M. R., Wise R., Dent J. The pharmacokinetics and tissue penetration of ofloxacin. J Antimicrob Chemother. 1984 Dec;14(6):647–652. doi: 10.1093/jac/14.6.647. [DOI] [PubMed] [Google Scholar]
  30. Maesen F. P., Teengs J. P., Baur C., Davies B. I. Quinolones and raised plasma concentrations of theophylline. Lancet. 1984 Sep 1;2(8401):530–530. doi: 10.1016/s0140-6736(84)92617-5. [DOI] [PubMed] [Google Scholar]
  31. Mayrer A. R., Andriole V. T. Urinary tract antiseptics. Med Clin North Am. 1982 Jan;66(1):199–208. doi: 10.1016/s0025-7125(16)31453-5. [DOI] [PubMed] [Google Scholar]
  32. Montay G., Goueffon Y., Roquet F. Absorption, distribution, metabolic fate, and elimination of pefloxacin mesylate in mice, rats, dogs, monkeys, and humans. Antimicrob Agents Chemother. 1984 Apr;25(4):463–472. doi: 10.1128/aac.25.4.463. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Notowicz A., Stolz E., van Klingeren B. A double blind study comparing two dosages of enoxacin for the treatment of uncomplicated urogenital gonorrhoea. J Antimicrob Chemother. 1984 Sep;14 (Suppl 100):91–94. doi: 10.1093/jac/14.suppl_c.91. [DOI] [PubMed] [Google Scholar]
  34. Panichi G., Pantosti A., Testore G. P. Norfloxacin (MK-0366) treatment of urinary tract infections in hospitalized patients. J Antimicrob Chemother. 1983 Jun;11(6):589–592. doi: 10.1093/jac/11.6.589. [DOI] [PubMed] [Google Scholar]
  35. Reeves D. S., Lacey R. W., Mummery R. V., Mahendra M., Bint A. J., Newsom S. W. Treatment of acute urinary infection by norfloxacin or nalidixic acid/citrate: a multi-centre comparative study. J Antimicrob Chemother. 1984 May;13 (Suppl B):99–105. doi: 10.1093/jac/13.suppl_b.99. [DOI] [PubMed] [Google Scholar]
  36. Sabbaj J., Hoagland V. L., Shih W. J. Multiclinic comparative study of norfloxacin and trimethoprim-sulfamethoxazole for treatment of urinary tract infections. Antimicrob Agents Chemother. 1985 Mar;27(3):297–301. doi: 10.1128/aac.27.3.297. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Shimada J., Yamaji T., Ueda Y., Uchida H., Kusajima H., Irikura T. Mechanism of renal excretion of AM-715, a new quinolonecarboxylic acid derivative, in rabbits, dogs, and humans. Antimicrob Agents Chemother. 1983 Jan;23(1):1–7. doi: 10.1128/aac.23.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Swanson B. N., Boppana V. K., Vlasses P. H., Rotmensch H. H., Ferguson R. K. Norfloxacin disposition after sequentially increasing oral doses. Antimicrob Agents Chemother. 1983 Feb;23(2):284–288. doi: 10.1128/aac.23.2.284. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Tsuei S. E., Darragh A. S., Brick I. Pharmacokinetics and tolerance of enoxacin in healthy volunteers administered at a dosage of 400 mg twice daily for 14 days. J Antimicrob Chemother. 1984 Sep;14 (Suppl 100):71–74. doi: 10.1093/jac/14.suppl_c.71. [DOI] [PubMed] [Google Scholar]
  40. Watt B., Chait I., Kelsey M. C., Newsom S. W., Newsom R. A., Smith J., Toase P. D., Deaney N. B., Round E. M., Vogel R. Norfloxacin versus cotrimoxazole in the treatment of uncomplicated urinary tract infections--a multi-centre trial. J Antimicrob Chemother. 1984 May;13 (Suppl B):89–94. doi: 10.1093/jac/13.suppl_b.89. [DOI] [PubMed] [Google Scholar]
  41. Wijnands W. J., van Herwaarden C. L., Vree T. B. Enoxacin raises plasma theophylline concentrations. Lancet. 1984 Jul 14;2(8394):108–109. doi: 10.1016/s0140-6736(84)90283-6. [DOI] [PubMed] [Google Scholar]
  42. Wise R., Andrews J. M., Danks G. In-vitro activity of enoxacin (CL-919), a new quinoline derivative, compared with that of other antimicrobial agents. J Antimicrob Chemother. 1984 Mar;13(3):237–244. doi: 10.1093/jac/13.3.237. [DOI] [PubMed] [Google Scholar]
  43. Wise R., Lockley R. M., Webberly M., Dent J. Pharmacokinetics of intravenously administered ciprofloxacin. Antimicrob Agents Chemother. 1984 Aug;26(2):208–210. doi: 10.1128/aac.26.2.208. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Wise R., Lockley R., Dent J., Webberly M. Pharmacokinetics and tissue penetration of enoxacin. Antimicrob Agents Chemother. 1984 Jul;26(1):17–19. doi: 10.1128/aac.26.1.17. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Wise R. Norfloxacin--a review of pharmacology and tissue penetration. J Antimicrob Chemother. 1984 May;13 (Suppl B):59–64. doi: 10.1093/jac/13.suppl_b.59. [DOI] [PubMed] [Google Scholar]
  46. Wolf R., Eberl R., Dunky A., Mertz N., Chang T., Goulet J. R., Latts J. The clinical pharmacokinetics and tolerance of enoxacin in healthy volunteers. J Antimicrob Chemother. 1984 Sep;14 (Suppl 100):63–69. doi: 10.1093/jac/14.suppl_c.63. [DOI] [PubMed] [Google Scholar]
  47. Wolff M., Regnier B., Daldoss C., Nkam M., Vachon F. Penetration of pefloxacin into cerebrospinal fluid of patients with meningitis. Antimicrob Agents Chemother. 1984 Sep;26(3):289–291. doi: 10.1128/aac.26.3.289. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Wolfson J. S., Hooper D. C. The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro. Antimicrob Agents Chemother. 1985 Oct;28(4):581–586. doi: 10.1128/aac.28.4.581. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES